Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OCTA-C1-INH pharmacokinetics and safety in adults with hereditary angioedema
ISRCTN36746902Phase 2Completed
- Sponsor
- Octapharma
- Start
- Sep 2020
- Modality
- Recombinant Proteins and Enzymes
01
Overview
Phase 2, open-label, single-arm trial of cinryze in hereditary angioedema (HAE), sponsored by Octapharma. Primary endpoint: Pharmacokinetics of OCTA-C1-INH by C1-INH activity. Started Sep 2020; status: completed.
02
Drugs
cinryze
03
Conditions
hereditary angioedema (HAE)
Beyond the preview
Go deeper on ISRCTN36746902.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN36746902.